TABLE 1.
Combination chemotherapy, type of drug interaction by pathogen, and suppression of resistancea
| Species and drug combination | Experimental system | Interaction | Reference or result |
|---|---|---|---|
| Pseudomonas aeruginosa | |||
| Meropenem + tobramycin | In vitro plate assay | Additive | 16 |
| Meropenem + levofloxacin | HFIM | Synergistic | 17 |
| Meropenem + levofloxacin | Murine pneumonia | Synergistic | 18 |
| Cefepime + tobramycin | HFIM | Additive | 19 |
| Meropenem + tobramycin | Murine pneumonia | Additive | 20 |
| Ceftolozane + tazobactam | HFIM | Potentiating | 21 |
| Klebsiella pneumoniae/Enterobacter cloacae/Escherichia coli | |||
| Ceftaroline + avibactam | HFIM | Potentiating | 22 |
| Ceftolozane + tazobactam | HFIM | Potentiating | 23 |
| Mycobacterium tuberculosis | |||
| Moxifloxacin + rifampin | HFIM | Antagonistic | 24 |
| Moxifloxacin + rifampin | HFIM | Antagonistic | 25 |
| Linezolid + rifampin | HFIM | Additive | 26 |
a
HFIM, hollow-fiber infection model. “Interaction” refers to the drug interaction for bacterial cell kill.